Cargando…

A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab

A 72-year-old woman presented to our hospital with elevation of serum transaminases. Her blood tests showed the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) negative. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were given for the diffus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xiangjuan, Ji, Tongtong, Xin, Shengliang, Xu, Jinghang, Yu, Yanyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755885/ https://www.ncbi.nlm.nih.gov/pubmed/36532005 http://dx.doi.org/10.3389/fimmu.2022.1083862

Ejemplares similares

Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy
por: Hayashi, Manabu, et al.
Publicado: (2018)

Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
por: Muraishi, Junichi, et al.
Publicado: (2017)

Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
por: Hara, Tasuku, et al.
Publicado: (2020)

Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival
por: Chen, Kai-Lin, et al.
Publicado: (2015)

PB2312: REACTIVATION OF HEPATITIS B VIRUS FOLLOWING RITUXIMAB IN B LYMPHOID HEMOPATHIES
por: Wafa, Miled, et al.
Publicado: (2023)

Late Hepatitis B reactivation after treatment with rituximab
por: Pereira, Sara Lacerda, et al.
Publicado: (2022)

Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets
por: Xu, Jinghang, et al.
Publicado: (2020)

Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis
por: Xin, Shengliang, et al.
Publicado: (2020)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab
por: Schmajuk, Gabriela, et al.
Publicado: (2017)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab
por: Yoo, Dae San, et al.
Publicado: (2020)

Capabilities of hepatitis B surface antigen are divergent from hepatitis B virus DNA in delimiting natural history phases of chronic hepatitis B virus infection
por: Zhang, Zhanqing, et al.
Publicado: (2022)

Diverse Functions of γδ T Cells in the Progression of Hepatitis B Virus and Hepatitis C Virus Infection
por: Hou, Wen, et al.
Publicado: (2021)

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
por: Felberg, Anna, et al.
Publicado: (2020)

Rituximab resistance in ITP and beyond
por: Xiao, Zhengrui, et al.
Publicado: (2023)

The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients
por: Peng, Jing, et al.
Publicado: (2022)

Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk
por: Min, Yu, et al.
Publicado: (2023)

KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B
por: Li, Wenting, et al.
Publicado: (2017)

Commentary: Hepatitis B virus infection: an insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk
por: Morozov, Sergey, et al.
Publicado: (2023)

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
por: Tieu, Joanna, et al.
Publicado: (2021)

Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab
por: Tischer-Zimmermann, Sabine, et al.
Publicado: (2023)

Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients
por: Song, Ahreum, et al.
Publicado: (2022)

A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience
por: Oh, Myung Jin, et al.
Publicado: (2013)

COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
por: Furlan, Anna, et al.
Publicado: (2021)

Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies
por: Sandhu, Praneet, et al.
Publicado: (2017)

In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application
por: Du, Yanqin, et al.
Publicado: (2021)

Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy
por: Yamauchi, Nobuhiko, et al.
Publicado: (2021)

Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases
por: Lamberts, Aniek, et al.
Publicado: (2018)

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
por: Ahmed, A. Razzaque, et al.
Publicado: (2018)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Screening and prevention of hepatitis C virus reactivation during chemotherapy
por: Li, Yuan-Rung, et al.
Publicado: (2021)

Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells
por: Webendörfer, Maximilian, et al.
Publicado: (2021)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate
por: Yamauchi, Ryo, et al.
Publicado: (2020)

High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection
por: Gu, Shuqin, et al.
Publicado: (2021)

Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Yibo, et al.
Publicado: (2021)

A Role for B Cells to Transmit Hepatitis C Virus Infection
por: Desombere, Isabelle, et al.
Publicado: (2021)

Editorial: Targeting the Immune System to Treat Hepatitis B Virus Infection
por: Meng, Zhongji, et al.
Publicado: (2022)

Role of epigenetic modification in interferon treatment of hepatitis B virus infection
por: Yang, Zhijing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ecmr5d4oheshchm40c6d5rlono